Nonselective inhibition of prostaglandin-endoperoxide synthases by naproxen ameliorates acute or chronic liver injury in animals

Experimental and Molecular Pathology

Volumn 96, Issue 1, 2014, Pages 27-35

  Bahde, Ralf ^a,b   Kapoor, Sorabh ^a   Gupta, Sanjeev ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Drug; Injury; Liver; Protection; Soluble factors

Indexed keywords

ALANINE AMINOTRANSFERASE; CARBON TETRACHLORIDE; MESSENGER RNA; NAPROXEN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE 1; PROSTAGLANDIN SYNTHASE 2; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILIARY TRACT DISEASE; CELL PROLIFERATION; CHRONIC DISEASE; CONTROLLED STUDY; DRUG DOSE COMPARISON; ENZYME INHIBITION; LIVER CELL CULTURE; LIVER FIBROSIS; LIVER INJURY; LIVER NECROSIS; LIVER PROTECTION; LIVER TOXICITY; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; STELLATE CELL;

DRUG; INJURY; LIVER; PROTECTION; SOLUBLE FACTORS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CELLS, CULTURED; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DRUG-INDUCED LIVER INJURY; END STAGE LIVER DISEASE; HEPATOCYTES; INFLAMMATION; MALE; MEMBRANE PROTEINS; NAPROXEN; NECROSIS; RATS; RATS, INBRED F344;

EID: 84888368248     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2013.10.017     Document Type: Article

References (32)

1. Albrecht C., Meijer D.K., Lebbe C., Sägesser H., Melgert B.N., Poelstra K., Reichen J. Targeting naproxen coupled to human serum albumin to nonparenchymal cells reduces endotoxin-induced mortality in rats with biliary cirrhosis. Hepatology 1997, 26:1553-1559.
2. Batts K.P., Ludwig J. Chronic hepatitis, and update on terminology and reporting. Am. J. Surg. Pathol. 1995, 19:1409-1417.
3. Begay C.K., Gandolfi A.J. Late administration of COX-2 inhibitors minimize hepatic necrosis in chloroform induced liver injury. Toxicology 2003, 185:79-87.
4. Benten D., Kumaran V., Joseph B., Schattenberg J., Popov Y., Schuppan D., Gupta S. Hepatocyte transplantation activates hepatic stellate cells with beneficial modulation of cell engraftment in rats. Hepatology 2005, 42:1072-1081.
5. Cheng J., Imanishi H., Iijima H., Shimomura S., Yamamoto T., Amuro Y., Kubota A., Hada T. Expression of cyclooxygenase 2 and cytosolic phospholipase A2 in the liver tissue of patients with chronic hepatitis and liver cirrhosis. Hepatol. Res. 2002, 23:185-195.
6. Enami Y., Bandi S., Kapoor S., Krohn N., Joseph B., Gupta S. Hepatic stellate cells promote hepatocyte engraftment in rat liver after prostaglandin-endoperoxide synthase inhibition. Gastroenterology 2009, 136:2356-2364.
7. Gagandeep S., Novikoff P.M., Ott M., Gupta S. Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines. Cancer Lett. 1999, 136:109-118.
8. Gaudio E., Barbaro B., Alvaro D., Glaser S., Francis H., Franchitto A., Onori P., Ueno Y., Marzioni M., Fava G., Venter J., Reichenbach R., Summers R., Alpini G. Administration of r-VEGF-A prevents hepatic artery ligation-induced bile duct damage in bile duct ligated rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291:G307-G317.
9. Gaudio E., Barbaro B., Alvaro D., Glaser S., Francis H., Ueno Y., Meininger C.J., Franchitto A., Onori P., Marzioni M., Taffetani S., Fava G., Stoica G., Venter J., Reichenbach R., De Morrow S., Summers R., Alpini G. Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. Gastroenterology 2006, 130:1270-1282.
10. Glaser S., Lam I.P., Franchitto A., Gaudio E., Onori P., Chow B.K., Wise C., Kopriva S., Venter J., White M., Ueno Y., Dostal D., Carpino G., Mancinelli R., Butler W., Chiasson V., DeMorrow S., Francis H., Alpini G. Knockout of secretin receptor reduces large cholangiocyte hyperplasia in mice with extrahepatic cholestasis induced by bile duct ligation. Hepatology 2010, 52:204-214.
11. Horrillo R., Planagumà A., González-Périz A., Ferré N., Titos E., Miquel R., López-Parra M., Masferrer J.L., Arroyo V., Clària J. Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor. J. Pharmacol. Exp. Ther. 2007, 323:778-786.
12. Huang Z., Velázquez C.A., Abdellatif K.R., Chowdhury M.A., Reisz J.A., DuMond J.F., King S.B., Knaus E.E. Ethanesulfohydroxamic acid ester prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs): synthesis, nitric oxide and nitroxyl release, cyclooxygenase inhibition, anti-inflammatory, and ulcerogenicity index studies. J. Med. Chem. 2011, 54:1356-1364.
13. Isfort R.J., Cody D.B., Richards W.G., Yoder B.K., Wilkinson J.E., Woychik R.P. Characterization of growth factor responsiveness and alterations in growth factor homeostasis involved in the tumorigenic conversion of mouse oval cells. Growth Factors 1998, 15:81-94.
14. Joseph B., Bhargava K.K., Trunco G., Kumaran V., Palestro C.J., Gupta S. Regulation of hepatobiliary transport activity and noninvasive identification of cytokine-dependent liver inflammation. J. Nucl. Med. 2005, 46:146-152.
15. Junqueira L.C., Bignolas G., Mourão P.A., Bonetti S.S. Quantitation of collagen - proteogylcan interaction in tissue sections. Connect. Tissue Res. 1980, 7:91-96.
16. Khanapure S.P., Garvey D.S., Janero D.R., Letts L.G. Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr. Top. Med. Chem. 2007, 7:311-340.
17. Kovacevic L., Bernstein J., Valentini R.P., Imam A., Gupta N., Mattoo T.K. Renal papillary necrosis induced by naproxen. Pediatr. Nephrol. 2003, 18:826-829.
18. Krohn N., Kapoor S., Enami Y., Follenzi A., Bandi S., Joseph B., Gupta S. Hepatocyte transplantation-induced liver inflammation is driven by cytokines-chemokines associated with neutrophils and Kupffer cells. Gastroenterology 2009, 136:1806-1817.
19. LeCouter J., Moritz D.R., Li B., Phillips G.L., Liang X.H., Gerber H.P., Hillan K.J., Ferrara N. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003, 299:890-893.
20. Mayoral R., Mollá B., Flores J.M., Boscá L., Casado M., Martín-Sanz P. Constitutive expression of cyclo-oxygenase 2 transgene in hepatocytes protects against liver injury. Biochem. J. 2008, 416:337-346.
21. Mohammed N.A., El Aleem S.A., El Hafiz H.A., McMahon R.F. Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis. J. Clin. Pathol. 2004, 57:350-354.
22. Nanji A.A., Miao L., Thomas P., Rahemtulla A., Khwaja S., Zhao A., Khwaja S., Tahan S.R., Dannenberg A.J. Dietary saturated fatty acids down-regulate cyclooxygenase-2 and tumor necrosis factor alfa and reverse fibrosis in alcohol-induced liver disease in the rat. Hepatology 1997, 26:1538-1545.
23. Núñez O., Fernández-Martínez A., Majano P.L., Apolinario A., Gómez-Gonzalo M., Benedicto I., López-Cabrera M., Boscá L., Clemente G., García-Monzón C., Martín-Sanz P. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 2004, 53:1665-1672.
24. Oe H., Kaido T., Mori A., Onodera H., Imamura M. Hepatocyte growth factor as well as vascular endothelial growth factor gene induction effectively promotes liver regeneration after hepatectomy in Solt-Farber rats. Hepatogastroenterology 2005, 52:1393-1397.
25. Ohayon O., Mawasi N., Pevzner A., Tryvitz A., Gildor T., Pines M., Rojkind M., Paizi M., Spira G. Halofuginone upregulates the expression of heparanase in thioacetamide-induced liver fibrosis in rats. Lab. Invest. 2008, 88:627-633.
26. Ott M., Rajvanshi P., Sokhi R.P., Alpini G., Aragona E., Dabeva M., Shafritz D.A., Gupta S. Differentiation-specific regulation of transgene expression in a diploid epithelial cell line derived from the normal F344 rat liver. J. Pathol. 1999, 187:365-373.
27. Piscaglia A.C., Shupe T.D., Oh S.H., Gasbarrini A., Petersen B.E. Granulocyte-colony stimulating factor promotes liver repair and induces oval cell migration and proliferation in rats. Gastroenterology 2007, 133:619-631.
28. Riazy M., Chen J.H., Steinbrecher U.P. VEGF secretion by macrophages is stimulated by lipid and protein components of OxLDL via PI3-kinase and PKCzeta activation and is independent of OxLDL uptake. Atherosclerosis 2009, 204:47-54.
29. Sahasrabuddhe V.V., Gunja M.Z., Graubard B.I., Trabert B., Schwartz L.M., Park Y., Hollenbeck A.R., Freedman N.D., McGlynn K.A. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J. Natl. Cancer Inst. 2012, 104:1808-1814.
30. Weiss T.S., Lichtenauer M., Kirchner S., Stock P., Aurich H., Christ B., Brockhoff G., Kunz-Schughart L.A., Jauch K.W., Schlitt H.J., Thasler W.E. Hepatic progenitor cells from adult human livers for cell transplantation. Gut 2008, 57:1129-1138.
31. Yu J., Hui A.Y., Chu E.S., Cheng A.S., Go M.Y., Chan H.L., Leung W.K., Cheung K.F., Ching A.K., Chui Y.L., Chan K.K., Sung J.J. Expression of a Cox-2 transgene in murine liver causes hepatitis. Gut 2007, 56:991-999.
32. Yu J., Hui A.Y., Chu E.S., Go M.Y., Cheung K.F., Wu C.W., Chan H.L., Sung J.J. The anti-inflammatory effect of celecoxib does not prevent liver fibrosis in bile duct-ligated rats. Liver Int. 2009, 29:25-36.